Introduction {#s1}
============

Acute myeloid leukemia (AML) is a heterogeneous disease in terms of karyotype and molecular abnormalities. The discovery of the classic karyotype abnormalities in AML such as the t(15;17) has been invaluable in enabling more accurate prognostic estimates, the development of specific therapies and the molecular monitoring of disease. However, approximately half of AML patients have no karyotype abnormality (CN-AML). This group of AML cases is presumably heterogeneous in all respects, and molecular monitoring is not possible unless there is an associated mutation. Recently it has been demonstrated that mutations of *FLT3*, *NPM1* and *CEBPA* genes are preferentially found in CN-AML. [@pone.0042334-Mrozek1] Nevertheless many cases do not possess such mutations and this imposes a severe limitation in understanding their specific pathophysiology and monitoring disease progression. We have chosen to study CN-AML with the aim of finding a restricted panel of genes which are mutated in the majority of cases. In a series of 84 CN-AML patients, we examined 16 genes with mutations that had previously been described in cases of CN-AML ([Table S1](#pone.0042334.s001){ref-type="supplementary-material"}). [@pone.0042334-Rocquain1], [@pone.0042334-AbdelWahab1], [@pone.0042334-Ishikawa1], [@pone.0042334-Abbas1], [@pone.0042334-Couronne1], [@pone.0042334-Schlenk1], [@pone.0042334-Carbuccia1], [@pone.0042334-Chou1], [@pone.0042334-Flach1], [@pone.0042334-Dicker1], [@pone.0042334-Shen1], [@pone.0042334-Thol1], [@pone.0042334-Beer1], [@pone.0042334-Pratcorona1], [@pone.0042334-Metzeler1], [@pone.0042334-Jankowska1] The characterisation of cases by the presence or absence of mutations in these selected genes should allow a molecular dissection of cases of CN-AML into different biological and prognostic groups, as well as achieving the long sought after goal of molecular monitoring of CN-AML.

Design and Methods {#s2}
==================

Patients {#s2a}
--------

A total of 84 AML patients (mean age 64, range 16 to 86, 23 patients under 60; 52 male, 32 female) with no cytogenetic abnormalities were recruited for mutational analysis, including 51 primary cases (mean age 60, range 16 to 86, 20 patients under 60; 27 male, 24 female) and 33 cases secondary to either MDS (n = 24) or CMML (n = 9) (mean age 70, range 51 to 81, 3 patients under 60; 25 male, 8 female). The karyotype was investigated again at the time of transformation in 31 of the 33 secondary cases, and found to be normal. An additional 100 cases were investigated for mutations in *ASXL1* from AML patients showing different karyotypic abnormalities. Some of the cases included in the present study (16 CN-AML and 51 cases with aberrant cytogenetics) have been previously analyzed for ASXL1 exon 12 mutations, and results reported elsewhere. [@pone.0042334-Boultwood1] All karyotypes were analyzed by conventional G-banding in at least 30 metaphases. Samples showing inv(16), t(8;21) or t(15;17) at karyotype were subjected to confirmation by molecular techniques. This study was approved by the ethics committees of the institutes involved: the John Radcliffe Hospital (Oxford 06/Q1606/110), the Royal Bournemouth Hospital (Bournemouth 9991/03/E) and the University of Navarre (Pamplona IRB00006933); written informed consent was received from all patients.

DNA sequencing and analysis {#s2b}
---------------------------

Genomic DNA was isolated from patient bone marrow or peripheral blood samples. Primers and PCR conditions for the 16 genes analyzed are detailed in [Table S2](#pone.0042334.s002){ref-type="supplementary-material"}. Relevant regions were selected for analysis ([Table S2](#pone.0042334.s002){ref-type="supplementary-material"}): exons 12 of *ASXL1* (NM_015338.5) and *NPM1* (NM_002520), exons 11 and 17 of *FLT3* (NM_004119), exon 14 of *JAK2* (NM_004972), entire coding region of *TET2* (NM_001127208.2), Exons 4 of *IDH1* (NM_005896) and *IDH2* (NM_002168), exons 3 to 8 of *RUNX1* (NM_001001890), exons 7--9 of *CBL* (NM_005188), exons 9 and 10 of *MPL* (NM_005373), exons 3 to 9 of *TP53* (NM_000546), exons 2 and 3 of *NRAS* (NM_002524.4) and *KRAS* (NM_033360), Exons 4 to 9 of *WT1* (NM_024426), exons 7 to 23 of *DNMT3A* (NM_022552) and exons 12 to 16 of *SF3B1* (NM_012433.2). PCR was performed using ThermoStart PCR Master Mix (Thermo Fisher Scientific), following the manufacturer\'s protocol. PCR products were purified and bidirectionally sequenced using the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 Genetic Analyzer. Sequence data were analyzed using Mutation Surveyor V3.25 (Softgenetics, State College, PA, USA). Two sided Fisher\'s exact test was performed to compare mutation frequencies in primary versus secondary cases, and in the analysis of cooperating mutations.

Results and Discussion {#s3}
======================

A total of 84 CN-AML patients were recruited for mutational analysis, including 51 primary cases and 33 cases secondary to either MDS (n = 24) or CMML (n = 9). The 16 genes analyzed were: *ASXL1*, *NPM1*, *FLT3*, *TET2*, *IDH1*, *IDH2*, *RUNX1*, *DNMT3A*, *NRAS*, *JAK2*, *WT1*, *CBL*, *SF3B1*, *TP53*, *KRAS* and *MPL*. The regions analysed for each gene are detailed in [Table S2](#pone.0042334.s002){ref-type="supplementary-material"}. The frequencies of mutation are shown in [Table 1](#pone-0042334-t001){ref-type="table"}. The most frequently mutated genes in primary cases were *NPM1* (60.8%) and *FLT3* (50.0%), and in secondary cases *ASXL1* (48.5%) and *TET2* (30.3%).

10.1371/journal.pone.0042334.t001

###### Frequency of mutations in normal karyotype AML samples.

![](pone.0042334.t001){#pone-0042334-t001-1}

                                                      All CN-AML samples (n = 84)   Primary AML (n = 51)   Secondary AML (n = 33)    p value   
  -------------------------------------------------- ----------------------------- ---------------------- ------------------------ ----------- ----------
  ***ASXL1***                                               **18 (21.4%)**                2 (3.9%)               10 (41.7%)         6 (66.7%)   \<0.0001
  ***NPM1***                                                **35 (41.7%)**               31 (60.8%)              3 (12.5%)          1 (11.1%)   \<0.0001
  ***FLT3***                                               **29/81 (35.8%)**            24/48 (50%)              4 (16.7%)          1 (11.1%)    0.0019
  ***JAK2***                                                 **3/60 (5%)**                  0/44                2/15 (13.3%)        1 (11.1%)    0.0404
  ***TET2***                                               **21/81 (25.9%)**           11/48 (22.9%)             4 (16.7%)          6 (66.7%)    0.6065
  ***IDH1***                                               **10/82 (12.2%)**            7/50 (14.0%)            3/23 (13.0%)            0        0.7327
  ***IDH2***                                               **10/82 (12.2%)**            7/50 (14.0%)            2/23 (8.7%)         1 (11.1%)    0.7327
  ***RUNX1***                                              **12/81 (14.8%)**             6 (11.8%)               4/21 (19%)         2 (22.2%)    0.3553
  ***CBL***                                                  **2 (2.4%)**                 2 (3.9%)                   0                  0        0.5172
  ***MPL***                                                      **0**                       0                       0                  0          1
  ***TP53***                                                 **1 (1.2%)**                    0                    1 (4.2%)              0        0.3929
  ***NRAS***                                                  **5 (6%)**                     0                   3 (12.5%)          2 (22.2%)    0.0077
  ***KRAS***                                                     **0**                       0                       0                  0          1
  ***WT1***                                                  **3 (3.6%)**                 3 (5.9%)                   0                  0        0.2758
  ***DNMT3A***                                              **14 (16.7%)**               13 (25.5%)               1 (4.2%)              0        0.0068
  ***SF3B1***                                                **2 (2.4%)**                    0                    2 (8.3%)              0        0.1515
  ***FLT3*** **mutations breakdown**                                                                                                           
  ***FLT3-ITD***                                           **27/81 (33.3%)**           23/48 (47.9%)             3 (12.5%)          1 (11.1%)    0.0008
  ***FLT3-TKD*** [\*](#nt101){ref-type="table-fn"}          **3/81 (3.7%)**             2/48 (4.2%)              1 (11.1%)              0          1
  ***IDH2*** **mutations breakdown**                                                                                                           
  ***IDH2-R140Q***                                         **9/82 (11.0%)**             6/50 (12.0%)            2/23 (8.7%)         1 (11.1%)      1
  ***IDH2-R172K***                                          **1/82 (1.2%)**             1/50 (12.0%)                 0                  0          1

One primary AML sample presented concomitant *FLT3-ITD* and *FLT3-TKD* mutations.

An analysis of the mutations occurring in more than 10% of cases revealed statistically significant associations ([Figure 1](#pone-0042334-g001){ref-type="fig"}, [Table S3](#pone.0042334.s003){ref-type="supplementary-material"}). In agreement with previous reports, *FLT3* and *DNMT3A* mutations were significantly associated with *NPM1* mutations, [@pone.0042334-Shen1] whereas patients with *ASXL1* mutations had significantly lower incidence of *NPM1* and *DNMT3A* mutations. [@pone.0042334-Carbuccia1], [@pone.0042334-Chou1] *IDH1* and *IDH2* mutations were mutually exclusive. With the exception of one patient, no cases with IDH1/2 mutation also had a *TET2* mutation. *IDH1* and *IDH2* mutations were less frequent in *TET2*-mutated than in *TET2*-wt patients, and this has been reported before. [@pone.0042334-Figueroa1], [@pone.0042334-Metzeler2] Concurrence of *IDH1/2* and *ASXL1* mutations was also a relatively infrequent event in our patient cohort ([Figure 1](#pone-0042334-g001){ref-type="fig"}). This observation is in agreement with a report on a series of 63 AML secondary to MPN cases. [@pone.0042334-AbdelWahab1]

![Concurrence of mutations in 16 genes analyzed in CN-AML samples.\
Columns show results for each of the 84 analysed cases. Solid boxes indicate mutated cases. Grey boxes mark unavailable data. *FLT3-ITD* mutations are indicated with top-half solid boxes and *FLT3-TKD* with bottom-half solid boxes. Similarly, *IDH2-R140Q* mutations are shown with top-half solid boxes and *IDH2-R172K* with bottom-half solid boxes.](pone.0042334.g001){#pone-0042334-g001}

*ASXL1* mutations were significantly more frequent in secondary AML compared to *de novo* AML cases (primary cases: 2/51, 3.9%; secondary to MDS/CMML: 16/33, 48.5%, p\<0.0001). We have previously reported a high prevalence of *ASXL1* mutations in advanced MDS. [@pone.0042334-Boultwood1] *NPM1*, *FLT3*, and *DNMT3A* mutations were significantly more common in primary CN-AML than in secondary AML cases ([Table 1](#pone-0042334-t001){ref-type="table"}). *NRAS*, *JAK2*, *SF3B1* and *TP53* mutations were exclusively present in secondary AML samples ([Table 1](#pone-0042334-t001){ref-type="table"}). Only 9.5% of the samples analyzed (8/84, 6 *de novo* and 2 post-MDS cases) showed no mutation in any of the genes tested. When considering only the *ASXL1*, *NPM1*, *FLT3*, *TET2*, *IDH1/2* and *RUNX1* gene analysis, 88% of *de novo* CN-AML included in this series presented at least one molecular marker. For secondary cases, 85% of patients carried mutations in at least one of these 7 genes.

Recent reports showed that *DNMT3A* mutations are associated with a poor outcome in AML, [@pone.0042334-Ley1], [@pone.0042334-Renneville1] and that the location of the mutations could have an impact in age-related risk classification. [@pone.0042334-Marcucci1] It is worth noting that in our series, *DNMT3A* was not found as a sole mutation suggesting that additional aberrations are needed to sustain leukemogenic development.

Approximately 70% of CN-AML cases secondary to either MDS or CMML presented mutations in at least one of *ASXL1*, *TET2*, *IDH1* or *IDH2* genes. Therefore, we chose to assess the presence and chronology of *ASXL1*, *TET2* and *IDH1/2* mutational events, in order to investigate whether they could have a role in disease development or evolution. We studied 15 MDS and 4 CMML cases that progressed to AML, for which at least two samples at different time-points were available. Remarkably, with the exception of two patients all of them possessed at least one gene mutation at some stage of the disease. The majority showed the same mutations at early and later stages of the disease, except one patient who developed an *IDH1* mutation at transformation, a second patient with a *TET2* mutation who acquired an additional *ASXL1* mutation at transformation, and another patient who developed a nonsense mutation of *ASXL1* at AML stage, and showed rapid disease evolution ([Table 2](#pone-0042334-t002){ref-type="table"}). On the basis of this study we therefore did not find any consistent patterns in mutation acquisition. A sensitive mutation analysis (such as allele-specific PCR) at early stages of AML in future studies could help clarify whether the mutations found in cases from later stage AML were already present as a minor pre-existing clone at the earlier stage, and if so, how it evolved as the disease progressed to AML.

10.1371/journal.pone.0042334.t002

###### Mutational analysis of serial samples from patients in transformation.
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  Sample ID       Disease stage   Age   Time from diagnosis (+months)                                                                       Cytogenetics                                                                                            ASXL1                                           TET2                      IDH1    IDH2                                                                                                   Comments
  -------------- --------------- ----- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------- ------------------------------------------- ------- ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient \#1         CMML        58                  0                                                                                     46,XY\[30\]                                                                                               wt                                           M1388I                      wt      wt    
                       AML                          (+45)                                        68,XXYYY,+3,+4,+der(6)x3,+7,+8,+8,+9,+11,+11,+12,+13,+17,+19,+19,+20,+21,+21,+22\[9\]/46,XY\[41\]                                                    wt                                           Q1445X                      wt      wt         Previously to this sampling, he was treated with azacitidine. After treatment, the original clone was replaced with an aberrant karyotype new one, now harbouring a different *TET2* mutation.
  Patient \#2         CMML        65                  0                                                                                     46,XY\[30\]                                                                               2242C\>CT; Q748X+2863A\>AT; T957S                            No mut                      wt      wt    
                       AML                          (+9)                                                                         46,XY,i(17)(q10)\[15\]/46,XY\[15\]                                                                   2242C\>CT; Q748X+2863A\>AT; T957S                            No mut                      wt      wt    
  Patient \#3         CMML        65                  0                                                                             47,XY,+8,add(21)(q22)\[30\]                                                                1902--1924delAGAGGCGGCCACCACTGCCATCG; E635RfsX15   2959_2962het_dupAGAC+2954_2957het_dupAAAC    wt      wt    
                       AML                          (+6)                                                             47,XY,+8,add(21)(q22)\[18\]/46,XY,+8,−21,add(21)(q22)\[7\]                                                                       wt                                             wt                        wt      wt     Previously to this sampling he underwent QT and BMT. The initial clone remitted, but after 5 months a new clone appeared, now including Monosomy 21, and having lost the previously detected mutations.
  Patient \#4         CMML        42                  0                                                                              45,XY,−7\[4\]/46,XY\[21\]                                                                                        wt                                             wt                        wt      wt    
                       AML                          (+5)                                                                             45,XY,−7\[47\]/46,XY\[3\]                                                                                        wt                                             wt                        wt      wt    
  Patient \#5          MDS        66                  0                                                                                     46,XY\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG; E635RfsX15                      wt                        wt      wt    
                       AML                          (+5)                                                                                    46,XY\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG; E635RfsX15                      wt                        wt      wt    
                       AML                          (+10)                                                                                   46,XY\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG; E635RfsX15                      wt                        wt      wt                                                                                       Sample after azacitidine treatment.
                       AML                          (+12)                                                                                   46,XY\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG; E635RfsX15                      wt                        wt      wt                                                                                       Sample after azacitidine treatment.
  Patient \#6          MDS        72                  0                                                                                     46,XY\[30\]                                                                                    1925het_insA; G643RfsX13                                 L34F                       wt      wt    
                       AML                          (+11)                                                                                   46,XY\[30\]                                                                                    1925het_insA; G643RfsX13                                 L34F                       wt      wt                                                                                Additional *JAK2*, *RUNX1* and *NRAS* mutations.
  Patient \#7          MDS        70                  0                                                                                     46,XY\[30\]                                                                                      1934dupG; G646WfsX12                                    wt                        wt      wt    
                   MDS (RAEB)                       (+8)                                                                                    46,XY\[30\]                                                                                      1934dupG; G646WfsX12                                    wt                        wt      wt    
                       AML                          (+15)                                                                                   46,XY\[30\]                                                                                      1934dupG; G646WfsX12                                    wt                        wt      wt                                                                                           Additional *NRAS* mutation.
  Patient \#8          MDS        76                  0                                                                                     46,XX\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG E635RfsX15                       wt                        wt      wt    
                       AML                          (+12)                                                                                   46,XX\[30\]                                                                        1902--1924delAGAGGCGGCCACCACTGCCATCG E635RfsX15                       wt                       R132C    wt    
  Patient \#9       MDS (RA)      77                  0                                                                                     46,XX\[30\]                                                                                               wt                                            Q403X                      wt      wt    
                      CMML                          (+8)                                                                                    46,XX\[30\]                                                                                      1934dupG G646WfsX12                                    Q403X                      wt      wt                                                                                            AML-transformed at (+40).
  Patient \#10      MDS (RA)      ND                  0                                                                                     46,XX\[30\]                                                                                      1934dupG G646WfsX12                                     wt                        wt      wt    
                      CMML                          (+12)                                                                                   46,XX\[30\]                                                                                      1934dupG G646WfsX12                                     ND                        wt      wt    
  Patient \#11         MDS        84                  0                                                                                     46,XX\[30\]                                                                                      1934dupG G646WfsX12                                   L1151P                      wt      wt    
                   MDS (RAEB)                       (+12)                                                                                   46,XX\[30\]                                                                                      1934dupG G646WfsX12                                   L1151P                      wt      wt    
  Patient \#12         MDS        76                  0                                                                                     46,XX\[30\]                                                                                      1934dupG G646WfsX12                                    Y867H                      wt     R140Q  
                   MDS (RAEB)                       (+3)                                                                                    46,XX\[30\]                                                                                      1934dupG G646WfsX12                                    Y867H                      wt     R140Q                                                                        Previously to this sample, she underwent one course of AraC.
  Patient \#13         MDS        64                  0                                                                                     46,XX\[30\]                                                                                            1934dupG                                          wt                        wt     R140Q  
                   MDS (RAEB)                       (+12)                                                                                   46,XX\[30\]                                                                                            1934dupG                                          wt                        wt     R140Q  
  Patient \#14         MDS        79                (+20)                                                                           46,XX,del(5)(q15∶q33)\[30\]                                                                              1934dupG G646WfsX12                                    S794X                      wt      wt    
                   MDS (RAEB)                       (+53)                                                                           46,XX,del(5)(q15∶q33)\[30\]                                                                              1934dupG G646WfsX12                                    S794X                      wt      wt    
  Patient \#15         MDS        80                  0                                                                                     46,XX\[30\]                                                                                               wt                                             wt                        wt      wt    
                       MDS                          (+1)                                                                                    46,XX\[30\]                                                                                               wt                                             wt                        wt      wt    
                       AML                          (+2)                                                                                    46,XX\[30\]                                                                                       2893C\>C/T; R965X                                      wt                        wt      wt                                                                        Non mutated for any of the 15 other genes included in this study.
  Patient \#16         MDS        71                  0                 45,XX,add(3)(p14),del(5)(q13∶q33),add(7)(q22),+8,−12,−13,−16,i(20)(q10),+mar1\[18\]/48,XX,+1,del(5)(q13∶q33),add(7)(q22),+8,−12,−13,+mar1,+mar2\[7\]                          wt                                             wt                        wt      wt    
                   MDS (RAEB)                       (+6)                45,XX,add(3)(p14),del(5)(q13∶q33),add(7)(q22),+8,−12,−13,−16,i(20)(q10),+mar1\[18\]/48,XX,+1,del(5)(q13∶q33),add(7)(q22),+8,−12,−13,+mar1,+mar2\[7\]                          wt                                             wt                        wt      wt                                                                      Later (+10), she developed four additional complex karyotype clones.
  Patient \#17     MDS (RAEB)     65                  0                                                                                     46,XY\[30\]                                                                                    1863--1873del L622RfsX9                                   wt                        wt      wt    
                       AML                          (+10)                                                                                   46,XY\[30\]                                                                                    1863--1873del L622RfsX9                                   wt                        wt      wt                                                                                        Additional *FLT3* mutation (ITD)
  Patient \#18      MDS (RA)      ND                  0                                                                                    45,XX,−7\[30\]                                                                        1934dupG G646WfsX12 (same mutation as M871)                         wt                        wt      wt    
                       AML                          (+8)                                                                                   45,XX,−7\[30\]                                                                                    1934dupG G646WfsX12                                     wt                        wt      wt    
  Patient \#19         MDS        ND                  0                                                                                     46,XX\[30\]                                                                                               wt                                             wt                        wt     R140Q  
                   MDS (RAEB)                       (+9)                                                                                    46,XX\[30\]                                                                                               wt                                             wt                        wt     R140Q  

In order to investigate whether the observed low incidence of *ASXL1* mutations is a specific characteristic of karyotypically normal *de novo* cases, or is a common feature of other subtypes of primary AML, we screened an additional cohort of 100 primary AML, including the most common karyotypic subgroups. Overall, only 8 out of 100 cases showed nonsense or frameshift mutations (8%) ([Table S4](#pone.0042334.s004){ref-type="supplementary-material"}), confirming that *ASXL1* mutations are less common in primary AML than in secondary AML.

This report concerns the analysis of the largest number of gene mutations in CN-AML studied to date. Our results show that 85% of CN-AML patients have mutations in one or more of 7 selected genes (*ASXL1*, *NPM1*, *FLT3*, *TET2*, *IDH1/2* and *RUNX1*). This finding will facilitate further analysis of this important group of patients by enabling CN-AML patients to be subdivided into groups with common mutation patterns. Detailed studies of the CN-AML subgroups in regard to their hematological features, prognosis, disease progression and treatment response will now be facilitated.
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